These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17105374)

  • 1. Epidermal growth factor receptor as a major anticancer drug target.
    Caponigro F; Milano A; Ottaiano A; Iaffaioli RV
    Expert Opin Ther Targets; 2006 Dec; 10(6):877-88. PubMed ID: 17105374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downstream intracellular effectors of epidermal growth factor receptor as targets for anticancer therapy.
    Milano A; De Rosa V; Iaffaioli RV; Caponigro F
    Expert Opin Ther Targets; 2007 Jun; 11(6):771-82. PubMed ID: 17504015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.
    Bianco R; Damiano V; Gelardi T; Daniele G; Ciardiello F; Tortora G
    Curr Pharm Des; 2007; 13(33):3358-67. PubMed ID: 18045190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor as a target for anti-cancer agent design.
    Cao J; Fang H; Wang B; Ma C; Xu W
    Anticancer Agents Med Chem; 2010 Jul; 10(6):491-503. PubMed ID: 20698825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
    Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
    Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
    Grünwald V; Hidalgo M
    J Natl Cancer Inst; 2003 Jun; 95(12):851-67. PubMed ID: 12813169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of EGFR inhibitors in nonsmall cell lung cancer.
    Ciardiello F; De Vita F; Orditura M; Tortora G
    Curr Opin Oncol; 2004 Mar; 16(2):130-5. PubMed ID: 15075904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy.
    Caraglia M; Marra M; Meo G; Addeo SR; Tagliaferri P; Budillon A
    Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):209-22. PubMed ID: 18221038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the EGF/HER Ligand-Receptor System in Cancer.
    Esparís-Ogando A; Montero JC; Arribas J; Ocaña A; Pandiella A
    Curr Pharm Des; 2016; 22(39):5887-5898. PubMed ID: 27426127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-epidermal growth factor receptor drugs in cancer therapy.
    Ciardiello F; Tortora G
    Expert Opin Investig Drugs; 2002 Jun; 11(6):755-68. PubMed ID: 12036420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy.
    Raymond E; Faivre S; Armand JP
    Drugs; 2000; 60 Suppl 1():15-23; discussion 41-2. PubMed ID: 11129168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules.
    Caraglia M; Santini D; Bronte G; Rizzo S; Sortino G; Rini GB; Di Fede G; Russo A
    Curr Drug Metab; 2011 Dec; 12(10):944-55. PubMed ID: 21787268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
    Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
    Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma.
    Prabhu VV; Devaraj N
    J Environ Pathol Toxicol Oncol; 2017; 36(2):151-158. PubMed ID: 29199595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on epidermal growth factor receptor inhibitors.
    Modi S; Seidman AD
    Curr Oncol Rep; 2002 Jan; 4(1):47-55. PubMed ID: 11734113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
    Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
    Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal Growth Factor Receptor (EGFR) and its Cross-Talks with Topoisomerases: Challenges and Opportunities for Multi-Target Anticancer Drugs.
    Chauhan M; Sharma G; Joshi G; Kumar R
    Curr Pharm Des; 2016; 22(21):3226-36. PubMed ID: 26907945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-).
    Hu L; Fan M; Shi S; Song X; Wang F; He H; Qi B
    Eur J Med Chem; 2022 Jan; 227():113963. PubMed ID: 34749202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight.
    Damare R; Engle K; Kumar G
    Phytother Res; 2024 May; 38(5):2406-2447. PubMed ID: 38433568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.